Aktuelle Entwicklungen in der regionalen Behandlung von peritonealen und pleuralen Tumoren (inkl. HIPEC und HITOC)

Piso, Pompiliu; Hofmann, Hans Stefan

doi:10.1055/a-0882-6545

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these results should be cautiously interpreted due to the limited number of included patients. A previous study showed that about 60% of patients with pleural metastases are secondary to extra thoracic malignancies, with breast cancer as the most common primary with incidence about 25% followed by lymphoma (10%), ovarian cancer (5%), and intraabdominal malignancies (5%) (18). The complete surgical cytoreduction of metastatic ovarian cancer in the abdominal cavity was shown to be an independent prognostic factor, however the role of CRS in thoracic cavity has scarcely been reported…”

Section: Discussionmentioning

confidence: 99%

“…The main finding of our study was a prolonged survival in selected patients with secondary pleural metastases after CRS+HITOC as a part of multimodal treatment approach with median overall survival of 39 months and median RFS/PFS of 14 months. Retrospective studies showed an encouraging survival of patients with pleural mesothelioma or thymus tumours with pleural involvement, who underwent a multimodal treatment approach including local interventions with CRS+HITOC ( 5 , 11 , 20 ). However, there is paucity of studies investigating the outcome of CRS+HITOC in patients with secondary pleural metastases as a part of multimodal concept.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases

Hassan,

Zimmermann,

Schmid

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe role of cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy (CRS+HITOC) for patients with secondary pleural metastases has scarcely been investigated.Patients and MethodsWe conducted a retrospective, multicentre study investigating the outcome of CRS+HITOC for 31 patients with pleural metastases from different primary tumours in four high-volume departments of thoracic surgery in Germany. The primary endpoint was overall survival (OS). Secondary endpoints included postoperative complications and recurrence/progression-free survival (RFS/PFS).ResultsThe primary tumour was non-small cell lung cancer in 12 (39%), ovarian cancer in 5 (16%), sarcoma in 3 (10%), pseudomyxoma peritonei in 3 (10%), and others in 8 (26%) patients. A macroscopic complete resection (R/1) could be achieved in 28 (90%) patients. Major postoperative complications as classified by Clavien-Dindo (III-V) were observed in 11 (35%) patients. The postoperative mortality rate was 10% (n=3). A total of 13 patients received additive chemotherapy (42%). The median time of follow up was 30 months (95% CI = 17– 43). The median OS was 39 months (95% CI: 34-44 months) with 1-month, 3-month, 1-, 3-, and 5-year survival estimates of 97%, 89%, 77%, 66%, and 41%. There was a significantly prolonged OS in patients who received additive chemotherapy compared to patients with only CRS+HITOC (median OS 69 vs 38 months; p= 0.048). The median RFS was 14 months (95% CI: 7-21 months).ConclusionsWe observed that CRS+HITOC is a feasible approach with reasonable complications and prolonged survival as a part of multimodal concept for highly selected patients with secondary pleural metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcome after cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy in patients with secondary pleural metastases

Hassan,

Zimmermann,

Schmid

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Der Einsatz chirurgischer Ansätze bei der Peritonealkarzinose und der Pleurakarzinose hat sich weiter konsolidiert, und die Indi-kationen, in denen das Verfahren mit gutem onkologischen Outcome durchgeführt werden sollte, wurden im Vergleich zu vor einigen Jahren weiter eingeschränkt [4]. In der vorliegenden Ausgabe stellen Piso und Koautoren in diesem Zusammenhang die Position der ACO, der Association Chirurgische Onkologie der DGAV (Deutsche Gesellschaft für Allgemein-und Viszeralchirurgie, http://aco-chirurgie.de/) zur aktuellen PRODIGE-7-Studie dar [5].…”

unclassified